Skip to main content


Fig. 1 | BMC Neurology

Fig. 1

From: Cerebro-spinal fluid biomarker levels: phosphorylated tau (T) and total tau (N) as markers for rate of progression in Alzheimer’s disease

Fig. 1

Cognitive status at baseline and CSF T-tau or P-tau by AT(N) biomarker profiles. a More impaired MMSE score at the start of ChEI therapy (time of AD diagnosis) showed a linear association with higher T-tau (rs = − 0.222, p = 0.012). b A negative correlation between the SATS patients’ MMSE score and P-tau (rs = − 0.204, p = 0.020) was also observed. c Worse ADAS-cog score at baseline demonstrated a linear relationship with higher T-tau (rs = 0.194, p = 0.030). Abbreviations: A+, abnormal CSF Aβ42; AD, Alzheimer’s disease; ADAS-cog, Alzheimer’s Disease Assessment Scale–cognitive subscale; ChEI, cholinesterase inhibitor; CSF, cerebro-spinal fluid; MMSE, Mini-Mental State Examination; (N)–, normal CSF T-tau; (N)+, abnormal CSF T-tau; P-tau, phosphorylated tau; SATS, Swedish Alzheimer Treatment Study; T–, normal CSF P-tau; T+, abnormal CSF P-tau; T-tau, total tau

Back to article page